Skip to content

Study · Case report or series · n = 1 · 2021

26 results

Necrotizing Pancreatitis Secondary to Dulaglutide Use

Bhat S, Goudarzi A

Journal of the Endocrine Society3 May 2021

PMCIDPMC8089879 (opens in a new tab)PepBankPUB-93986146
Read at sourceSource pageAsk about this study
Jump to 26 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study26

26 results from studies that gave the peptide. 26 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A man with diabetes developed severe necrotizing pancreatitis after dulaglutide exposure.

    In plain wordsA man with diabetes developed severe pancreatic inflammation and tissue death after dulaglutide exposure.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNecrotizing pancreatitis
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Source sentences

    Summary
    We report a case of acute severe necrotizing pancreatitis most likely attributed to dulaglutide.
    3 context sentences
    Summary · context
    Initial CT showed an enlarged pancreas with peripancreatic stranding and slightly diminished enhancement consistent with early signs of necrotizing pancreatitis.
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  2. 02HumanCase report or seriesSafety outcome

    A man exposed to dulaglutide presented with diffuse abdominal pain.

    In plain wordsA man exposed to dulaglutide developed widespread abdominal pain.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAbdominal pain
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Source sentences

    Summary
    Clinical Case: A 69-year-old man presented lethargic with diffuse abdominal pain associated with nausea and vomiting of 1-day duration.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  3. 03HumanCase report or seriesSafety outcome

    A man exposed to dulaglutide presented with nausea.

    In plain wordsA man exposed to dulaglutide developed nausea.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNausea
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Source sentences

    Summary
    Clinical Case: A 69-year-old man presented lethargic with diffuse abdominal pain associated with nausea and vomiting of 1-day duration.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  4. 04HumanCase report or seriesSafety outcome

    A man exposed to dulaglutide presented with vomiting.

    In plain wordsA man exposed to dulaglutide developed vomiting.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableVomiting
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Source sentences

    Summary
    Clinical Case: A 69-year-old man presented lethargic with diffuse abdominal pain associated with nausea and vomiting of 1-day duration.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  5. 05HumanCase report or seriesOther

    A man with pancreatitis after dulaglutide exposure had lipase of 2800 units/mL.

    In plain wordsA man with pancreatitis after dulaglutide exposure had lipase of 2800 units/mL.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdmission lipase
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    Lipase
    2800 units/mL
    admission

    Source sentences

    Summary
    Initial workup showed lipase 2800 units/mL
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  6. 06HumanCase report or seriesOther

    A man with pancreatitis after dulaglutide exposure had amylase of 1185 units/mL.

    In plain wordsA man with pancreatitis after dulaglutide exposure had amylase of 1185 units/mL.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdmission amylase
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    Amylase
    1185 units/mL
    admission

    Source sentences

    Summary
    amylase 1185 units/mL
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  7. 07HumanCase report or seriesOther

    A man with pancreatitis after dulaglutide exposure had lactate of 12.6 mmol/L.

    In plain wordsA man with pancreatitis after dulaglutide exposure had lactate of 12.6 mmol/L.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdmission lactate
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    Lactate
    12.6 mmol/L
    admission

    Source sentences

    Summary
    lactate 12.6 mmol/L
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  8. 08HumanCase report or seriesOther

    A man with pancreatitis after dulaglutide exposure had white blood cells of 20 x 109/L.

    In plain wordsA man with pancreatitis after dulaglutide exposure had white blood cells of 20 x 109/L.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdmission white blood cells
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    White blood cells
    20 x 109/L
    admission

    Source sentences

    Summary
    white blood cells 20 x 109/L
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  9. 09HumanCase report or seriesOther

    A man with pancreatitis after dulaglutide exposure had glucose of 348 mg/dL.

    In plain wordsA man with pancreatitis after dulaglutide exposure had blood sugar of 348 mg/dL.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdmission glucose
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    Glucose
    348 mg/dL
    admission

    Source sentences

    Summary
    glucose 348 mg/dL
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  10. 10HumanCase report or seriesOther

    A man with pancreatitis after dulaglutide exposure had AST of 30 unit/L.

    In plain wordsA man with pancreatitis after dulaglutide exposure had AST of 30 unit/L.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdmission AST
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    AST
    30 unit/L
    admission

    Source sentences

    Summary
    AST 30 unit/L
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  11. 11HumanCase report or seriesOther

    A man with pancreatitis after dulaglutide exposure had hematocrit of 51.5%.

    In plain wordsA man with pancreatitis after dulaglutide exposure had hematocrit of 51.5%.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdmission hematocrit
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    Hematocrit
    51.5%
    admission

    Source sentences

    Summary
    hematocrit 51.5%
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  12. 12HumanCase report or seriesOther

    A man with pancreatitis after dulaglutide exposure had blood urea nitrogen of 24 mg/dL.

    In plain wordsA man with pancreatitis after dulaglutide exposure had blood urea nitrogen of 24 mg/dL.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdmission blood urea nitrogen
    Study

    n = 1

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    Blood urea nitrogen
    24 mg/dL
    admission

    Source sentences

    Summary
    blood urea nitrogen 24 mg/dL
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  13. 13HumanCase report or seriesOther

    A man with pancreatitis after dulaglutide exposure had creatinine of 1.57 mg/dL.

    In plain wordsA man with pancreatitis after dulaglutide exposure had creatinine of 1.57 mg/dL.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdmission creatinine
    Study

    n = 1

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    Creatinine
    1.57 mg/dL
    admission

    Source sentences

    Summary
    serum creatinine 1.57 mg/dL
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  14. 14HumanCase report or seriesOther

    A man with pancreatitis after dulaglutide exposure had calcium of 8.1 mg/dL.

    In plain wordsA man with pancreatitis after dulaglutide exposure had calcium of 8.1 mg/dL.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdmission calcium
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    Calcium
    8.1 mg/dL
    admission

    Source sentences

    Summary
    calcium 8.1 mg/dL.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  15. 15HumanCase report or seriesSafety outcome

    A man with pancreatitis after dulaglutide exposure became hypoxic and required intubation.

    In plain wordsA man with pancreatitis after dulaglutide exposure needed a breathing tube after oxygen levels fell.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableHypoxia
    Study

    n = 1

    Outcome group
    Adverse events · Respiratory
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Source sentences

    Summary
    The patient became increasingly hypoxic and hypotensive and required intubation and triple pressor support to maintain adequate perfusion.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  16. 16HumanCase report or seriesSafety outcome

    A man with pancreatitis after dulaglutide exposure developed hypotension requiring triple pressor support.

    In plain wordsA man with pancreatitis after dulaglutide exposure needed medicines to maintain blood pressure.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableHypotension
    Study

    n = 1

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Source sentences

    Summary
    The patient became increasingly hypoxic and hypotensive and required intubation and triple pressor support to maintain adequate perfusion.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  17. 17HumanCase report or seriesOther

    A man with pancreatitis after dulaglutide exposure had hematocrit of 35.7% on the second hospital day.

    In plain wordsA man with pancreatitis after dulaglutide exposure had hematocrit of 35.7% on the second hospital day.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDay two hematocrit
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    Hematocrit
    35.7%
    second hospital day

    Source sentences

    Summary
    On the second day of hospitalization, his hematocrit was 35.7%, blood urea nitrogen 37 mg/dL, calcium 6.8 mg/dL, and bicarbonate 21 mmol/L.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  18. 18HumanCase report or seriesOther

    A man with pancreatitis after dulaglutide exposure had blood urea nitrogen of 37 mg/dL on the second hospital day.

    In plain wordsA man with pancreatitis after dulaglutide exposure had blood urea nitrogen of 37 mg/dL on the second hospital day.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDay two blood urea nitrogen
    Study

    n = 1

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    Blood urea nitrogen
    37 mg/dL
    second hospital day

    Source sentences

    Summary
    On the second day of hospitalization, his hematocrit was 35.7%, blood urea nitrogen 37 mg/dL, calcium 6.8 mg/dL, and bicarbonate 21 mmol/L.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  19. 19HumanCase report or seriesOther

    A man with pancreatitis after dulaglutide exposure had calcium of 6.8 mg/dL on the second hospital day.

    In plain wordsA man with pancreatitis after dulaglutide exposure had calcium of 6.8 mg/dL on the second hospital day.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDay two calcium
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    Calcium
    6.8 mg/dL
    second hospital day

    Source sentences

    Summary
    On the second day of hospitalization, his hematocrit was 35.7%, blood urea nitrogen 37 mg/dL, calcium 6.8 mg/dL, and bicarbonate 21 mmol/L.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  20. 20HumanCase report or seriesOther

    A man with pancreatitis after dulaglutide exposure had bicarbonate of 21 mmol/L on the second hospital day.

    In plain wordsA man with pancreatitis after dulaglutide exposure had bicarbonate of 21 mmol/L on the second hospital day.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDay two bicarbonate
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    Bicarbonate
    21 mmol/L
    second hospital day

    Source sentences

    Summary
    On the second day of hospitalization, his hematocrit was 35.7%, blood urea nitrogen 37 mg/dL, calcium 6.8 mg/dL, and bicarbonate 21 mmol/L.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  21. 21HumanCase report or seriesSafety outcome

    A man with pancreatitis after dulaglutide exposure had peak AST of 209 unit/L.

    In plain wordsA man with pancreatitis after dulaglutide exposure had a peak AST blood level of 209 unit/L.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicablePeak AST
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    AST
    209 unit/L
    peak

    Source sentences

    Summary
    AST and ALT peaked at 209 and 398 unit/L respectively.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  22. 22HumanCase report or seriesSafety outcome

    A man with pancreatitis after dulaglutide exposure had peak ALT of 398 unit/L.

    In plain wordsA man with pancreatitis after dulaglutide exposure had a peak ALT blood level of 398 unit/L.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicablePeak ALT
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    ALT
    398 unit/L
    peak

    Source sentences

    Summary
    AST and ALT peaked at 209 and 398 unit/L respectively.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  23. 23HumanCase report or seriesSafety outcome

    A man with pancreatitis after dulaglutide exposure had a Ranson score of 7 at 48 hours.

    In plain wordsA man with pancreatitis after dulaglutide exposure had a severity score of 7 at 48 hours.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableRanson score
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Measurements

    Ranson score
    7 score
    48 hours

    Source sentences

    Summary
    Calculated 48 hours Ranson’s score was 7.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  24. 24HumanCase report or seriesSafety outcome

    A man with pancreatitis after dulaglutide exposure developed cholecystitis requiring a cholecystostomy tube.

    In plain wordsA man with pancreatitis after dulaglutide exposure developed gallbladder inflammation requiring a drainage tube.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableCholecystitis
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Source sentences

    Summary
    He developed cholecystitis secondary to inflammatory damage of the biliary tract and received a cholecystostomy tube.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  25. 25HumanCase report or seriesSafety outcome

    A man with pancreatitis after dulaglutide exposure recovered fully and entered rehabilitation.

    In plain wordsA man with pancreatitis after dulaglutide exposure recovered fully and was discharged to rehabilitation.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableRecovery
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Source sentences

    Summary
    The patient made a full recovery and was discharged to a rehabilitation unit.
    2 context sentences
    Summary · context
    His past medical history consisted of type 2 diabetes, hyperlipidemia, hypertension, and hypothyroidism.
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
  26. 26HumanCase report or seriesSafety outcome

    A man exposed to dulaglutide presented with lethargy during severe necrotizing pancreatitis.

    In plain wordsA man exposed to dulaglutide was lethargic when he presented with severe pancreatic inflammation.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableLethargy
    Study

    n = 1

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    0.75 mg weekly, increased to 1.5 mg weekly · three monthsAs given in this study (human).

    Source sentences

    Summary
    Clinical Case: A 69-year-old man presented lethargic with diffuse abdominal pain associated with nausea and vomiting of 1-day duration.
    2 context sentences
    Summary · context
    Dulaglutide was added three months prior at 0.75 mg weekly, and the dose was increased to 1.5 mg weekly three days before presentation, the patient having received one such dose.
    Summary · context
    We report a case of acute severe necrotizing pancreatitis most likely attributed to dulaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.